HTD Balance Sheet - Corcept Therapeutics Inc

Watchlist Manager

Watchlist

Price: 66.1 EUR

Market Cap: €6.8B

Financial profile · Q3 FY2026

An expanding commercial portfolio with investment-sensitive operating leverage

Corcept's product-led revenue base has expanded across the multi-year record, while operating earnings fluctuate as commercial and research spending changes. Modest property and equipment spending lets operating cash generation flow through as free cash flow, although stock compensation and working-capital movements make cash conversion less smooth.

What is developing

Recent results extend product-sales growth and show a sharp operating recovery, while Lifyorli adds a new commercial revenue stream. The change matters to the earnings profile, but one quarter does not establish a lasting margin trajectory as commercialization costs continue to rise.

What matters next

Whether Lifyorli sales continue to grow while operating margin holds up as commercialization spending increases.

Metric	FY2016 Dec 2016	FY2017 Dec 2017	FY2018 Dec 2018	FY2019 Dec 2019	FY2020 Dec 2020	FY2021 Dec 2021	FY2022 Dec 2022	FY2023 Dec 2023	FY2024 Dec 2024	FY2025 Dec 2025
Cash & Cash Equivalents	51.5m	31.1m	41.6m	31.3m	76.2m	77.6m	66.3m	135.6m	127.7m	120.5m
Cash Equivalents	51.5m	31.1m	41.6m	31.3m	76.2m	77.6m	66.3m	135.6m	127.7m	120.5m
Short-Term Investments	—	57.7m	165.1m	244.7m	364.5m	145.9m	365.3m	232.7m	257.5m	256.9m
Total Receivables	9.9m	28.2m	17.6m	19.9m	26.2m	27.6m	31.1m	41.1m	54m	59.8m
Accounts Receivables	9.9m	15.3m	17.6m	19.9m	26.2m	27.6m	31.1m	41.1m	54m	59.8m
Other Receivables	0	12.9m	0	0	0	0	0	0	0	0
Inventory	2.3m	4.6m	4.7m	5.4m	4.9m	5m	6.1m	7.7m	12.4m	12.9m
Other Current Assets	2m	2.7m	7.7m	6m	6.7m	10.3m	30.4m	41.6m	20.1m	35.4m
Total Current Assets	65.7m	124.2m	236.8m	307.4m	478.5m	266.5m	499.3m	458.6m	471.6m	485.5m
PP&E Net	200k	500k	700k	4.5m	4.2m	1.5m	1.8m	315k	8m	6.5m
PP&E Gross	200k	500k	700k	4.5m	4.2m	1.5m	1.8m	—	—	—
Accumulated Depreciation	(500k)	(400k)	(600k)	(1.3m)	(1.9m)	(2.9m)	(3.7m)	—	—	—
Long-Term Investments	—	15.3m	0	39.4m	36.2m	112.3m	4.9m	57.2m	219.8m	160.3m
Other Long-Term Assets	2.9m	80.6m	74.2m	61.1m	52.9m	43.5m	77.5m	105.4m	141.1m	184.4m
Total Assets	68.8m	220.5m	311.7m	412.3m	571.7m	423.8m	583.4m	621.5m	840.6m	836.7m
Accounts Payable	2.3m	8.6m	8.3m	7.5m	10.6m	6.9m	12m	17.4m	15.4m	40.4m
Accrued Liabilities	10.4m	21m	25.8m	30.8m	36.9m	40.1m	60.4m	85.3m	125.2m	125.6m
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Current Portion of Long-Term Debt	14.7m	0	—	—	—	—	—	—	—	—
Other Current Liabilities	0	—	1.5m	500k	—	500k	100k	1.8m	191k	—
Total Current Liabilities	27.4m	29.6m	35.6m	38.8m	47.5m	47.5m	72.5m	104.5m	140.8m	166.1m
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Other Liabilities	—	—	200k	2.3m	900k	400k	9.1m	10.3m	20.2m	22.8m
Total Liabilities	27.4m	29.6m	35.8m	41.1m	48.4m	48m	81.6m	114.8m	161m	188.8m
Common Stock	100k	100k	100k	100k	100k	100k	100k	133k	136k	140k
Retained Earnings	(322.3m)	(193.1m)	(117.7m)	(23.6m)	82.5m	195m	296.4m	402.5m	543.7m	643.4m
Additional Paid In Capital	363.5m	384.1m	417.2m	457.1m	516.1m	591.3m	662.3m	738.5m	832.1m	968.6m
Treasury Stock	—	—	(23.7m)	(62.7m)	(75.8m)	(410.4m)	(456.1m)	(635.1m)	(696.2m)	(966.6m)
Other Equity	—	(100k)	(100k)	300k	400k	(200k)	(900k)	609k	(217k)	2.3m
Total Equity	41.4m	191m	275.9m	371.2m	523.3m	375.8m	501.8m	506.7m	679.6m	647.8m
Total Liabilities & Equity	68.8m	220.5m	311.7m	412.3m	571.7m	423.8m	583.4m	621.5m	840.6m	836.7m
Common Shares Outstanding	112.7m	114.7m	115m	114.5m	116.7m	105.9m	131m	103.4m	105.1m	106m